Why is Pfizer falling/rising?

As of 29-Jul, Pfizer Ltd. is experiencing a slight increase in its stock price, currently at 5,280.75, reflecting a change of 5.75 or 0.11% upward. However, the stock has been underperforming recently, having fallen consecutively for the last two days with a total decline of 1.54%. In the past week, it has underperformed its sector by 1.73%, and over the last month, the stock has decreased by 7.37%, while the year-to-date return is modestly positive at 0.51%. Despite these challenges, the company boasts a high management efficiency with a return on equity (ROE) of 19.67% and a high dividend yield of 3.79%, which may provide some support for its price.
Broader market context indicates that Pfizer's performance has been weaker compared to the benchmark Sensex, which has seen a decline of 1.03% over the past week and 3.24% over the past month. While Pfizer's long-term growth prospects appear limited, with net sales growing at an annual rate of only 1.18% over the last five years, its current valuation is considered expensive with a price-to-book ratio of 5.7. This premium valuation, alongside a PEG ratio of 2.4, suggests that investors may be cautious, especially given the stock's negative return of 1.82% over the past year despite a profit increase of 16.1%.